Sugi Predict

Sugi Predict / Compounds / SCHEMBL2799343

SCHEMBL2799343

SCHEMBL2799343

CC[C@@H]1CN(C(=O)OC(C)(C)C)CCN1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ MAPK1 P28482 1/20 0.40
▸ HPGD P15428 1/20 0.39
▸ PARP1 P09874 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37
▸ SCN9A Q15858 2/20 0.36
▸ EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18683 1.00 NR1H2 (0.43) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL334410 1.00 NR1H2 (0.43) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL6981501 0.91 MEN1 (0.46) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL20742255 0.89 NR1H2 (0.40) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL20742257 0.89 NR1H2 (0.40) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL29476305 0.89 NR1H2 (0.40) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL10219106 0.88 NR1H2 (0.41) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL1468234 0.88 NR1H2 (0.41) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL10219104 0.88 NR1H2 (0.41) NR1H2MAPTMEN1ALDH1A1KMT2A
SCHEMBL1462710 0.88 NR1H2 (0.50) NR1H2MAPTMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104046246-B The chemical-mechanical planarization of tungsten-containing substrate 气体产品与化学公司 2016-06-15 — — CN claimed
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 — — US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 — — EP claimed
EP-3802500-B1 MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2026-05-27 — — EP disclosed
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 — — WO disclosed
EP-4482583-B1 ZWITTERIONIC ANTIBACTERIAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2026-04-01 — — EP disclosed
US-12479825-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2025-11-25 — — US disclosed
US-12479828-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2025-11-25 — — US disclosed
US-12441735-B2 Nitrogen-containing heterocyclic compound having NRF2 activation effect CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-10-14 — — US disclosed
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 — — US disclosed
US-20250304568-A1 PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE ABBVIE INC (US) 2025-10-02 — — US disclosed
US-20100216812-A1 Cyclopropyl Amide Derivatives ASTRAZENECA AB (SE) 2010-08-26 — — US disclosed
CN-101600720-A Phosphoinositide 3-kinase inhibitor compounds and using method HOFFMANN LA ROCHE (CH) 2009-12-09 — — CN disclosed
US-20090286974-A1 Derivative having ppar agonistic activity SHIONOGI & CO., LTD. (JP) 2009-11-19 — — US disclosed
EP-1343775-B1 PIPERAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-06-04 — — EP disclosed
US-7022707-B2 Piperazine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-04-04 — — US disclosed
US-20040235859-A1 Novel piperazine derivatives ADAMS DAVID REGINALD (GB) 2004-11-25 — — US disclosed
EP-1343775-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-17 — — EP disclosed
US-20020143020-A1 Novel piperazine derivatives VERNALIS RESEARCH LIMITED (GB) 2002-10-03 — — US disclosed
WO-2002048124-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304568-A1 PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE BTK, TYMP, LYN NR1H2 3306/4885MAPT 4765/4885MEN1 4061/4885
US-12441735-B2 Nitrogen-containing heterocyclic compound having NRF2 activation effect KEAP1, NFE2L2, BACH1 NR1H2 47/4885MAPT 4531/4885MEN1 2182/4885
US-12479825-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R NR1H2 564/4885MAPT 1929/4885MEN1 644/4885
US-20020143020-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 NR1H2 1100/4885MAPT 2976/4885MEN1 1694/4885
US-20100216812-A1 Cyclopropyl Amide Derivatives HRH4, HRH2, HRH3 NR1H2 63/4885MAPT 1670/4885MEN1 3982/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN NR1H2 1189/4885MAPT 26/4885MEN1 2719/4885
US-20090286974-A1 Derivative having ppar agonistic activity PPARD, PPARA, PPARG NR1H2 9/4885MAPT 4787/4885MEN1 4624/4885
US-12479828-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R NR1H2 564/4885MAPT 1929/4885MEN1 644/4885
US-20040235859-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 NR1H2 1100/4885MAPT 2976/4885MEN1 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.